{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:01:41Z","timestamp":1791309701790,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129077","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:45:30Z","timestamp":1788057930000},"page":"129077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged\u00a0\u226545\u00a0years in Spain"],"prefix":"10.1016","volume":"91","author":[{"given":"Muloongo","family":"Simuzingili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fern\u00e1ndez-Sober\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cossrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2026.129077_bb0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129077_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1028525","article-title":"Global burden of lower respiratory infections during the last three decades","volume":"10","author":"Safiri","year":"2023","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129077_bb0015","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1080\/21645515.2021.1923348","article-title":"Burden of pneumococcal disease among adults in southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis","volume":"17","author":"Navarro-Torn\u00e9","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/antibiotics12010172","article-title":"Burden of hospitalizations related to pneumococcal infection in Spain (2016\u20132020)","volume":"12","author":"Gil-Prieto","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.vaccine.2026.129077_bb0025","author":"European Centre for Disease Prevention and Control"},{"issue":"36","key":"10.1016\/j.vaccine.2026.129077_bb0030","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129077_bb0035","author":"European Centre for Disease Prevention and Control"},{"key":"10.1016\/j.vaccine.2026.129077_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"van Aalst","year":"2018","journal-title":"Travel Med Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129077_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175224","article-title":"Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain","volume":"12","author":"C\u00e0mara","year":"2017","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129077_bb0050","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129077_bb0055","first-page":"142","article-title":"Epidemiology of pneumococcal diseases in Spain after the introduction of pneumococcal conjugate vaccines","volume":"39","author":"Marimon","year":"2021","journal-title":"Enfermedades infecciosas y microbiologia clinica (English ed)"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129077_bb0060","doi-asserted-by":"crossref","first-page":"106204","DOI":"10.1016\/j.jinf.2024.106204","article-title":"Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)","volume":"89","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129077_bb0065","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/microorganisms11061376","article-title":"Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review","volume":"11","author":"Teixeira","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.129077_bb0070","author":"R"},{"key":"10.1016\/j.vaccine.2026.129077_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2026.100571","article-title":"Evolution of invasive pneumococcal disease in adults in Spain (2009\u20132024): impact of conjugate vaccines PCV20 y PCV21","volume":"8","author":"Garc\u00eda","year":"2026","journal-title":"Open Respir Arch"},{"issue":"36","key":"10.1016\/j.vaccine.2026.129077_bb0080","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1016\/j.vaccine.2023.07.016","article-title":"\u201ccost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain,\u201d (in eng)","volume":"41","author":"Cantarero","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129077_bb0085","author":"Ministerio de Sanidad (Ministry of Health)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129077_bb0090","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.semerg.2018.09.005","article-title":"Adult community acquired pneumonia vaccination: 2018 update of the positioning of the pneumonia prevention expert group","volume":"44","author":"Redondo","year":"2018","journal-title":"Semergen"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0095","article-title":"Vaccination against community-acquired pneumonia in Spanish adults: practical recommendations by the NeumoExperts prevention group","volume":"12","author":"Redondo","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0100","article-title":"Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 Western European countries and the United States","volume":"8","author":"Noharet-Koenig","year":"2023","journal-title":"MDM Policy Pract"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129077_bb0105","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1080\/21645515.2019.1690884","article-title":"Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in northern Spain","volume":"16","author":"Rivero-Calle","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.anpede.2024.503713","article-title":"Immunisation schedule of the Pediatric Spanish association: 2025 recommendations","volume":"102","author":"\u00c1lvarez Garc\u00eda","year":"2025","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"10.1016\/j.vaccine.2026.129077_bb0115","author":"I. L. Centre"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129077_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2279394","article-title":"Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: a systematic review of published and grey literature","volume":"19","author":"Arya","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129077_bb0125","doi-asserted-by":"crossref","DOI":"10.37201\/req\/033.2025","article-title":"Pneumococcal vaccination coverage: residential care unit of the Community of Madrid","volume":"38","author":"Mart\u00edn-Caro \u00c1lvarez","year":"2025","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.vaccine.2026.129077_bb0195","series-title":"Informe epidemiol\u00f3gico sobre la situaci\u00f3n de la enfermedad neumoc\u00f3cica invasora en Espa\u00f1a. A\u00f1o 2024 Madrid","author":"C. N. d. E. I. d. S. C. III","year":"2024"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129077_bb0135","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s40121-024-01067-1","article-title":"Cost-effectiveness analysis of the use of V116, a 21-valent pneumococcal conjugate vaccine, in vaccine-na\u00efve adults aged\u226565 years in the United States","volume":"13","author":"Yi","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.129077_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2026.100819","article-title":"The health and economic burden of invasive pneumococcal diseases attributable to PCV21 or PCV20 serotypes among adults aged \u226518 years in Switzerland","volume":"31","author":"Simuzingili","year":"2026","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.129077_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126985","article-title":"Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada","volume":"54","author":"Ximenes","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13696998.2024.2445429","article-title":"Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach","volume":"28","author":"Mueller","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2026.129077_bb0155","author":"Stoecker"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","article-title":"Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands","volume":"22","author":"de Boer","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.129077_bb0165","first-page":"1","article-title":"Lifetime health and economic burden of invasive pneumococcal diseases attributable to V116 serotypes among adults in the United States","author":"Yi","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129077_bb0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","article-title":"\u201cSpanish recommendations on economic evaluation of health technologies,\u201d (in eng)","volume":"11","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2026.129077_bb0130","author":"Instituto Nacional de Estad\u00edstica"},{"key":"10.1016\/j.vaccine.2026.129077_bb0175","author":"World Bank Group"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129077_bb0180","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.129077_bb0185","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/ofid\/ofy209.021","article-title":"151. Evaluation of pneumococcal vaccine effectiveness against invasive pneumococcal disease among US Medicare beneficiaries \u226565 years old","volume":"5","author":"Pilishvili","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129077_bb0190","series-title":"Coberturas de vacunaci\u00f3n en personas adultas con condiciones de riesgo 2024","author":"C. d. S. Direcci\u00f3n General de Salud P\u00fablica","year":"2025"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129077_bb0200","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40121-024-00988-1","article-title":"\u201clifetime health and economic burden of invasive pneumococcal diseases attributable to V116 serotypes among adults in the United States,\u201d (in eng)","volume":"13","author":"Yi","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.129077_bb0205","author":"Center for Disease Control and Prevention"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129077_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106204","article-title":"Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)","volume":"89","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129077_bb0215","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13696998.2025.2496070","article-title":"Economic evaluation of PCV21 in vaccine-na\u00efve adults aged 19\u201364 years with underlying medical conditions in the United States","volume":"28","author":"Yi","year":"2025","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129077_bb0220","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jval.2024.03.511","article-title":"EE212 evaluating the potential health and economic impact of V116, an adult specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in the United States","volume":"27","author":"Yi","year":"2024","journal-title":"Value Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:31:40Z","timestamp":1790537500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0264410X26008868"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged\u00a0\u226545\u00a0years in Spain","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129077"}}